{"abstract": "The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen\u2019s 24-year monopoly led by its Epogen drug.", "web_url": "https://www.nytimes.com/2012/03/28/health/policy/fda-approves-new-anemia-drug.html", "snippet": "The Food and Drug Administration approved a new anemia drug called Omontys for dialysis patients, which will end Amgen\u2019s 24-year monopoly led by its Epogen drug.", "lead_paragraph": "It has been one of the most lucrative monopolies of all time, yielding the biotechnology company Amgen roughly $40 billion in sales over 23 years. ", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [], "headline": {"main": "F.D.A. Approves New Anemia Drug", "kicker": null, "content_kicker": null, "print_headline": "For Amgen, A Monopoly Is Ending", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Inventions and Patents", "rank": 1, "major": "N"}, {"name": "subject", "value": "Kidneys", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Affymax Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 5, "major": "N"}, {"name": "subject", "value": "ANEMIA", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Food and Drug Administration", "rank": 7, "major": "N"}], "pub_date": "2012-03-27T18:06:12+0000", "document_type": "article", "news_desk": "Business", "section_name": "Health", "subsection_name": "Money & Policy", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c03dab71-9d54-5896-ac84-0ae3376c95e1", "word_count": 1146, "uri": "nyt://article/c03dab71-9d54-5896-ac84-0ae3376c95e1"}